Press Releases

Scleroderma Diagnostics and Therapeutics Market with Size ,Growth, Financial Overview, Product Overview and Scope, Estimation to 2022-2030

Share This Article

Global Scleroderma Diagnostics and Therapeutics Market: Snapshot

The scleroderma therapeutics and diagnostics market exhibits high potential due to untapped needs and is set to grow rapidly in the near future due to the increasing focus globally on treatment of orphan diseases. The lack of approved drugs in the market makes it a highly opportune condition for players to convert their innovative drug ideas into successful treatment methods for this rare chronic inflammatory disease.

Get the sample copy of report@ https://qyresearchmedical.com/sample/112007

The global scleroderma diagnostics and therapeutics market was valued at US$1,689.7 mn in 2017 and is projected to expand at a CAGR of 10.3% from 2017 to 2024 to reach US$3,663.8 mn by 2024.

Physician and Patient Preference to make Immunosuppressive Agents Leading Drug Category

Presently, there is no approved drug for treatment of this orphan disease. Although drugs to manage symptomatic relief are available in the scleroderma therapeutics market, the treatment of scleroderma is challenging for a physician, since no two patients are alike in the progress of their disease. Thus, a host of different drugs are prescribed to every patient, depending on the extent, severity and nature of their symptoms.

It has been observed that patient consumption patterns in the global scleroderma diagnostics and therapeutics market are inclined towards immunosuppressive agents, which have shown to provide relief against several symptoms in both systemic and localized scleroderma cases. Moreover, of the very few treatments identified to efficaciously modify the course of scleroderma, physicians often recommend immunosuppressive agents to manage the most common symptoms of the disease. The segment, as a result, accounts for the dominant share in the global market.

Prostacyclin analogues have been found to have a potent effect in treating systemic scleroderma patients who suffer from pulmonary arterial hypertension. However, these drugs are expensive and thus, even though a smaller sub-set of patients is administered with these agents, their market value is high. This segment grabbed a significant share of the global scleroderma therapeutics market in the recent past; however, the share of this segment is anticipated to slightly decline by 2024 owing to availability of cheaper alternatives within this segment.

View full report@ https://qyresearchmedical.com/report/scleroderma-diagnostics-and-therapeutics-market-drug-class-corticosteroids-immunosuppressive-agents-endothelin-receptor-agonists-calcium-channel-blockers-pde-5-inhibitors-chelating-agents-prostacyclin-analo-017-2030/112007

Developed Regions to Continue to Command Dominance

Owing to better diagnostic and treatment rates, in part due to proactive awareness-raising initiatives by various foundations, have aided North America and Europe gain the predominant share in the global scleroderma diagnostics and therapeutics market. North America and Europe held significant share of the global scleroderma therapeutics market in the recent past. This is attributed to presence of renowned pharmaceutical companies, research organizations, and institutes in the regions, which are focused on finding a standard treatment for the condition.

The North America and Europe markets for scleroderma diagnostics and therapeutics are expected to retain their dominance in the global scleroderma diagnostics and therapeutics market throughout the forecast period, exhibiting significant CAGR over the period between 2017 and 2024. The ongoing cutting-edge research pertaining to scleroderma will aid the growth of a niche scleroderma diagnostics and therapeutics market in these regions.

Asia Pacific represents some of the world’s key emerging economies, which have the potential to adopt quickly to new therapies, provided they are available at reasonable costs. Due to the price-sensitive nature of the market, as well as availability of cheaper generics and reasonable clinical diagnostic rates compared to North America and Europe, the market for Asia Pacific gained the third position in terms of market share in 2015. The Asia Pacific market will also retain its position in the global market over the forecast period, with factors such as large population and high unmet needs working in favor of market expansion in the region.

Actelion Pharmaceuticals, Inc., Boehringer Ingelheim, Bayer AG, Cytori Therapeutics, Inc., Corbus Pharmaceutical Holdings Inc, Cumberland Pharmaceuticals, Inc., Gilead Sciences, Inc., Pfizer, Inc., and Sanofi are some of the key players operating in the global scleroderma diagnostics and therapeutics market.

Global Scleroderma Diagnostics and Therapeutics Market: Research Methodology

The report has been prepared after an elaborate primary and secondary research phase. Thus, the analysis of the scleroderma diagnostics and therapeutics market presented in reliable to a high degree. The primary research phase involved carrying out telephonic as well face-to-face interviews with industry experts along with e-mail interactions. Primary research represent major part of research efforts along with a secondary research phase. Industry stakeholders who participated in the primary research phase include CEOs, VPs, market intelligence managers, marketing/product managers, and national sales managers. Purchasing managers, technical experts, suppliers and traders were some other stakeholders who were reached out in the primary research phase. Rheumatologists, dermatologists, and physicians treating scleroderma patients were also reached out in the primary research phase of the making of the report.

Purchase Complete Report Now@ https://qyresearchmedical.com/report/checkout/112007/2900

Secondary research phase involved reaching out to industry-centric databases for data collection followed by data scrutiny. Secondary sources reached out include key players’ product literature, annual reports, relevant business documents, and trade journals. Some other secondary sources reached out include trade journals, technical writings, government websites, trade associations, Internet sources, and online paid databases.

Secondary research sources reached out for the study include stock analyst websites, company website sources, governmental organizations and public portals, Orange Book – FDA, U.S. Centers for Disease Control and Prevention, European Centre for Disease Prevention and Control, Clinicaltrials.gov, Clinicaltrialsregister.eu, journals and other publications.

TABLE OF CONTENT

Chapter 1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

Chapter 2. Assumptions and Research Methodology

Chapter 3. Executive Summary: Global Scleroderma Diagnostics and Therapeutics Market

Chapter 4. Market Overview
4.1. Introduction
4.1.1. Drug Class Definition
4.1.2. Industry Developments
4.2. Market Dynamics
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunity
4.3. Porters Five Forces Analysis
4.4. Global Scleroderma Diagnostics and Therapeutics Market Analysis and Forecasts, 2014–2024
4.5. Scleroderma Diagnostics and Therapeutics Market Outlook
4.6. Scleroderma : Overview of Clinical Trials

Chapter 5. Global Scleroderma Therapeutics Market Analysis and Forecasts, By Indication
5.1. Key Findings
5.2. Introduction
5.3. Market Size (US$ Mn) Forecast, by Indication
5.3.1. Localized
5.3.2. Systemic
5.4. Market Attractiveness Analysis, by Indication, 2015
5.5. Key Trends and Developments

Chapter 6. Global Scleroderma Therapeutics Market Analysis and Forecasts, By Drug Class
6.1. Key Findings
6.2. Introduction
6.3. Market Size (US$ Mn) Forecast, by Drug Class
6.3.1. Corticosteroids
6.3.2. Immunosuppressive Agents
6.3.3. Endothelin receptor antagonists
6.3.4. Calcium Channel Blockers
6.3.5. PDE-5 Inhibitors
6.3.6. Chelating Agents
6.3.7. Prostacyclin analogues
6.3.8. Others
6.4. Market Attractiveness Analysis, by Drug Class, 2015
6.5. Key Trends and Developments

Chapter 7. Global Scleroderma Therapeutics Market Analysis and Forecasts, By Region
7.1. Key Findings
7.2. Introduction
7.3. Market Size (US$ Mn) Forecast, by Region
7.3.1. North America
7.3.2. Europe
7.3.3. Asia Pacific
7.3.4. Latin America
7.3.5. Middle East & Africa
7.4. Market Attractiveness Analysis, by Region, 2015
7.5. Key Trends

Chapter 8. North America Scleroderma Therapeutics Market Analysis and Forecast
8.1. Key Findings
8.2. Introduction
8.3. Market Size (US$ Mn) Forecast, by Indication
8.3.1. Localized
8.3.2. Systemic
8.4. Market Size (US$ Mn) Forecast, by Drug Class
8.4.1. Corticosteroids
8.4.2. Immunosuppressive Agents
8.4.3. Endothelin receptor antagonists
8.4.4. Calcium Channel Blockers
8.4.5. PDE-5 Inhibitors
8.4.6. Chelating Agents
8.4.7. Prostacyclin analogues
8.4.8. Others
8.5. Market Size (US$ Mn) Forecast, by Country
8.5.1. U.S.
8.5.2. Canada
8.6. Market Attractiveness Analysis, by Indication, 2015
8.7. Market Attractiveness Analysis, by Drug Class, 2015
8.8. Key Trends

Chapter 9. Europe Scleroderma Therapeutics Market Analysis and Forecast
9.1. Key Findings
9.2. Introduction
9.3. Market Size (US$ Mn) Forecast, by Indication
9.3.1. Localized
9.3.2. Systemic
9.4. Market Size (US$ Mn) Forecast, by Drug Class
9.4.1. Corticosteroids
9.4.2. Immunosuppressive Agents
9.4.3. Endothelin receptor antagonists
9.4.4. Calcium Channel Blockers
9.4.5. PDE-5 Inhibitors
9.4.6. Chelating Agents
9.4.7. Prostacyclin analogues
9.4.8. Others
9.5. Market Size (US$ Mn) Forecast, by Country
9.5.1. U.K.
9.5.2. Germany
9.5.3. France
9.5.4. Rest of Europe
9.6. Market Attractiveness Analysis, by Indication 2015
9.7. Market Attractiveness Analysis, by Drug Class, 2015
9.8. Key Trends

Chapter 10. Asia Pacific Scleroderma Therapeutics Market Analysis and Forecast

……

Purchase Complete Report Now@ https://qyresearchmedical.com/report/checkout/112007/2900

You can place an order or ask any questions, please feel free to contact sales@qyresearchmedical.com | +1 9197 992 333

About Us

QYResearch Medical, focuses on custom research, management consulting, IPO consulting, industry chain research, and data base & seminar services. The company owns large basic databases (such as National Bureau of Statistics Database, Customs Import and Export Database, Industry Association Database, etc.), expert resources (including industry experts who own more than 10 years experiences on marketing or R&D in industries of healthcare services, medical technology & devices, etc.), professional survey team (the team members obtained more than 3 years market survey experience and more than 2 years deep expert interview experience), and excellent data analysis team (SPSS statistics and PPT graphics process team).

QYResearch Medical has more than 4000 global well-known customers, covering more than 30 industries including pharmaceuticals, medical technology & devices, healthcare services etc. Company services cover one-stop solution as Data-Analysis-Suggestion-Consulting Implementation. Research regions cover China, US, EU, Asia, Middle East and Africa, South America, Australia, and other regions in the world.

For Latest Update Follow Us:

https://www.linkedin.com/company/qyresearch-medical/

https://www.facebook.com/QYResearch-Medical-108186514228917/

https://twitter.com/qyresearchmedi

Show More

Related Articles

Back to top button